
Eledon Pharmaceuticals, a clinical-stage biotech company, develops an anti-CD40L antibody for people with type 1 diabetes and difficult-to-control blood sugars.
eledon.comCrawled Nov 6, 2026
The page highlights that transplanted kidneys often fail within 10–15 years, forcing many patients to repeat the transplant-dialysis cycle.
Eledon’s work is driven by caregivers and patient families seeking better ways to support those in need.
Eledon seeks to attract and retain professionals focused on advancing next-generation therapies to improve patient outcomes.
Dr. Hovland oversees Eledon’s regulatory, quality, and safety functions as Chief Regulatory Officer. He brings over 20 years of pharmaceutical R&D experience, contributing to the global development and registration of multiple pharmaceutical products.
Dr. Hillson has served as a member of the Board of Directors of Eledon Pharmaceuticals, Inc. since July 2021. Dr. Hillson currently serves as Senior Vice President of Clinical Development at Provention Bio (a Sanofi Company), a clinical stage biotech, purchased by Sanofi for $2.9 billion in 2023, focused on debilitating and life-threatening immune-mediated disease […]
Mr. McBride has served as a member of the Board of Directors of Eledon Pharmaceuticals, Inc. (formerly Novus Therapeutics, Inc.) since May 2017. Mr. McBride previously served as Chief Operating Officer, Chief Financial Officer, and interim Chief Financial Officer of Tokai Pharmaceuticals from 2014 until 2017. Prior to Tokai, Mr. McBride founded and served as President of […]
Dr. Lee has served on Eledon Pharmaceuticals’ board since December 2020. From 2021, he founded and led Esker Therapeutics as CEO, and previously served as Chief Development Officer at another company.
Mr. Katkin has served as Chairman of the Board of Directors of Eledon Pharmaceuticals, Inc. since the acquisition of Otic Pharma, Ltd. by Eledon Pharmaceuticals (formerly Novus Therapeutics, Inc.) in May 2017. Prior to the acquisition, Mr. Katkin served as Chairman of the Board of Directors for Otic Pharma from 2015 to 2017. Mr. Katkin served as […]
Dr. Perrin joined Eledon Pharmaceuticals as President and Chief Scientific Officer after founding and leading Anelixis Therapeutics. He has 20 years of drug development experience in R&D roles.
Eledon’s mission is to improve transplant outcomes by targeting the CD40 Ligand pathway, offering potential advantages over existing immunomodulatory therapies.
Eledon Pharmaceuticals reports that **10 patients with type 1 diabetes achieved 100% insulin independence** after receiving tegoprubart following islet transplantation in a study led by UChicago Medicine. The company highlights progress in its pipeline while releasing first-quarter 2026 financial results.
Eledon Pharmaceuticals reports early clinical results from a study of **tegoprubart** in **12 patients with type 1 diabetes** following islet transplantation, led by **UChicago Medicine**. The treatment shows updated outcomes from the fourth quarter and full-year 2025 performance metrics.
Eledon Pharmaceuticals secures FDA Orphan Drug designation for **tegoprubart**, expanding its use to prevent allograft rejection in **liver transplantation**. The biotech firm previously obtained orphan designations for tegoprubart in **pancreatic islet cell transplantation** and **amyotrophic lateral sclerosis (ALS)** treatment. The designation accelerates development and regulatory review for rare disease therapies.
Eledon Pharmaceuticals reports positive Phase 2 trial results for tegoprubart in kidney transplantation, demonstrating favorable efficacy, safety, and tolerability. The data supports the drug’s progression into Phase 3 development. The company outlines key business achievements and its outlook for 2026.
Eledon reports Phase 2 BESTOW trial results showing tegoprubart’s efficacy in preventing kidney transplant rejection. Patients treated with tegoprubart maintained an average 12-month estimated glomerular filtration rate (eGFR) of about **69 mL/min/1.73 m²** after one year post-transplant. The findings were presented at the **American Society of Nephrology’s Kidney Week 2025** conference, highlighting potential benefits for long-term kidney function in transplant recipients.